Table S1-S8 from Urinary tumor DNA MRD analysis to identify responders to neoadjuvant immunotherapy in muscle-invasive bladder cancer

Table S1. Clinicopathological characteristics of 20 patients in our study. Table S2. Representativeness of study participants. Table S3. Adverse events associated with toripalimab. Table S4. SNVs and InDels of therapy-naïve neoplastic tissues detected by whole exome sequencing. Table S5. SNVs and InDels of basal urine samples detected by whole exome sequencing. Table S6. SNVs and InDels detected by personalized MRD panel sequencing. Table S7. SNVs and InDels detected by the fixed actionable/hotspot panel sequencing. Table S8. Mutational measurements of each urine/plasma sample in our study.